Neurocrine Biosciences | NBIX

Stock Price
144.10
Daily Change
3.70 2.64%
Monthly
12.20%
Yearly
19.91%
Q3 Forecast
142.90

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Acadia Pharmaceuticals 25.26 -0.24 -0.94% 57.19% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
ALKERMES 29.94 1.02 3.53% 11.47% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
Dynavax Technologies 10.06 0.08 0.80% -8.79% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
Halozyme Therapeutics 74.93 1.53 2.08% 26.55% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Prothena 8.55 0.34 4.14% -57.94% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Repligen 124.56 3.98 3.30% -15.31% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Teva Pharmaceutical Industries 6,275.00 -65.00 -1.03% -9.12% Sep/04
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Neurocrine Biosciences traded at $144.10 this Friday September 5th, increasing $3.70 or 2.64 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences gained 12.20 percent. Over the last 12 months, its price rose by 19.91 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 142.90 by the end of this quarter and at 139.38 in one year, according to Trading Economics global macro models projections and analysts expectations.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.